MLYS
Mineralys Therapeutics, Inc.Company with tickers: MLYS
CIK
1933414
CUSIP
603170101
Shares Outstanding
82,498,101
13F Activity (30d)
201 filings
197 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $45,340,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Research & Development | $24,365,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Operating Income | $-45,340,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Net Income | $-39,339,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Basic) | $-0.47 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Diluted) | $-0.47 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |